The medical division of Bambino Gesù Ospedale Pediatrico (IRCCS), Rome, has conducted an open-label pilot study to evaluate the feasibility, safety and effectiveness of non-invasive focal mechanical vibrations (NIFMV) generated by Equistasi®.
This study involved a cohort of 10 patients with childhood ataxia, a phenomenological category including different conditions still lacking of effective symptomatic therapies.
Through the assessment of both clinical rating scales and spatio-temporal gait parameters via standardized gait analysis, we observed that a 4 weeks long treatment with medical device Equistasi® was safe and provided significantly different effects in stride features of patients with slow/non progressive cerebellar ataxia and Friedreich’s Ataxia.
Non-invasive focal mechanical vibrations (NIFMV) now represent a strategy of increasing interest to improve motor control in different neurological diseases and have produced encouraging preliminary results when used in the treatment of movement disorders and ataxia in adults. Equistasi® is a wearable device based on nanotechnology, transforming thermal variations into mechanical energy with focal vibrations.
The results of this study suggest that vibrations emitted by the medical stimulator Equistasi® could support locomotion of patients with childhood slow/non progressive cerebellar ataxia with preserved sensory system and no signs of peripheral neuropathy.
Future studies are definitely necessary to confirm these preliminary results and define criteria for successful Equistasi-based treatment and NIFMV-based treatment. However, this step is undoubtedly another success for medical research, a hope for those suffering from Ataxia and a stimulating factor for Equistasi®.
*Copyright: © 2018 Schirinzi, Romano, Favetta, Sancesario, Burattini, Summa, Della Bella, Castelli, Bertini, Petrarca and Vasco.